Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1.
Por:
Tabar AI, Prieto, L, Alba P, Nieto A, Rodríguez M, Torrecillas M, Huertas B, Gómez E, Fernandez F, Blanca M, Rodríguez D and Palacios R
Publicada:
1 jul 2019
Ahead of Print:
14 mar 2019
Resumen:
There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata.
Filiaciones:
Tabar AI:
Complejo Hospitalario de Navarra, Pamplona, Spain
:
Hospital Universitario Dr. Peset, Valencia, Spain
Alba P:
Hospital de Manises, Valencia, Spain
Nieto A:
Hospital Universitario La Fe, Valencia, Spain
Rodríguez M:
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Torrecillas M:
Hospital Universitario Nuestra Señora del Perpetuo Socorro, Albacete, Spain
Huertas B:
Hospital del Sureste, Arganda del Rey, Madrid, Spain
Gómez E:
Hospital Universitario de Ciudad Real, Spain
Fernandez F:
Hospital General. Universitario de Alicante, Spain
Blanca M:
Hospital Regional Universitario Carlos Haya, Málaga, Spain
Rodríguez D:
Diater Laboratorios S.A., Leganés, Madrid. Spain
Palacios R:
Diater Laboratorios S.A., Leganés, Madrid. Spain
Open Access
|